Bal Pharma Limited — Board Meeting, 11-08-2025: Outcome of Board Meeting

Bal Pharma's board approved Q1 FY25 consolidated financial results: Revenue from operations at ₹65.87 Cr and net profit at ₹0.20 Cr. The company will hold its 38th AGM on Sep 25, 2025, with book closure from Sep 19-25 for dividend entitlement. An Employee Stock Option Plan-2025 was approved, pending shareholder nod. Management notes confidence in recovering ₹9.69 Cr and ₹1.55 Cr from subsidiaries Lifezen Healthcare and Balace Clinic LLP, despite their losses and negative net worth, anticipating revival through fresh funds and marketing.